Literature DB >> 27032021

Effectiveness of Intraductal Meibomian Gland Probing for Obstructive Meibomian Gland Dysfunction.

Zuleyha Sik Sarman1, Bulent Cucen, Nursen Yuksel, Abdulkadir Cengiz, Yusuf Caglar.   

Abstract

PURPOSE: To evaluate the short-term effectiveness of intraductal meibomian gland probing using modified Maskin cannulas in patients with obstructive meibomian gland dysfunction.
METHODS: The study prospectively included 58 eyes of 30 patients with a diagnosis of meibomian gland dysfunction who were refractory to medical treatment for at least 6 months. The patients were divided into 4 groups according to the number of probing procedures applied. During probing, sterile modified Maskin probes 2, 2.5, 4, and 6 mm in length were used. A tarsal massage was recommended after medical treatment. Preoperatively, then postoperatively at 1 week, 1 month, and 3 months, the Schirmer 1 test was performed, tear break-up time was measured, and images of the anterior segment were recorded. In addition, the Ocular Surface Disease Index questionnaire was completed at baseline and at 3 months.
RESULTS: In all groups, there were no statistically significant differences between Schirmer 1 test results at preoperative and postoperative 3 months, but tear break-up time values measured at baseline and at 3 months differed significantly (5 seconds, 13 seconds, P < 0.001). In the analyses of anterior segment photographs of all patients, statistically significant postprocedural decreases in conjunctival hyperemia (P < 0.0001) and eyelid margin vascularization (P = 0.004) were detected, and the later Ocular Surface Disease Index scores showed a significant improvement between preop and 3 months.
CONCLUSIONS: A procedure using modified Maskin probes was effective and reliable in the short term for patients with meibomian gland dysfunction.

Entities:  

Mesh:

Year:  2016        PMID: 27032021     DOI: 10.1097/ICO.0000000000000820

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

Review 1.  Advances in dry eye disease treatment.

Authors:  Erin C O'Neil; Matthew Henderson; Mina Massaro-Giordano; Vatinee Y Bunya
Journal:  Curr Opin Ophthalmol       Date:  2019-05       Impact factor: 3.761

2.  Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction.

Authors:  Steven L Maskin; Whitney R Testa
Journal:  Br J Ophthalmol       Date:  2017-06-07       Impact factor: 4.638

3.  Meibography guided intraductal meibomian gland probing using real-time infrared video feed.

Authors:  Steven L Maskin; Sreevardhan Alluri
Journal:  Br J Ophthalmol       Date:  2020-02-27       Impact factor: 4.638

4.  Clinically Relevant Immune-Cellular Metrics of Inflammation in Meibomian Gland Dysfunction.

Authors:  Yureeda Qazi; Ahmad Kheirkhah; Caroline Blackie; Monique Trinidad; Candice Williams; Andrea Cruzat; Donald R Korb; Pedram Hamrah
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-12-03       Impact factor: 4.799

5.  Clinical results of Intraductal Meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive Meibomian gland dysfunction: a randomized controlled trial.

Authors:  Xiaodan Huang; Qiyu Qin; Linping Wang; Jiao Zheng; Lin Lin; Xiuming Jin
Journal:  BMC Ophthalmol       Date:  2019-10-28       Impact factor: 2.209

Review 6.  Non-pharmaceutical treatment options for meibomian gland dysfunction.

Authors:  Reiko Arita; Shima Fukuoka
Journal:  Clin Exp Optom       Date:  2020-01-13       Impact factor: 2.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.